RU2014104384A - Производные никотиновой кислоты в качестве метаботропных глутаматных рецепторов - Google Patents

Производные никотиновой кислоты в качестве метаботропных глутаматных рецепторов Download PDF

Info

Publication number
RU2014104384A
RU2014104384A RU2014104384/04A RU2014104384A RU2014104384A RU 2014104384 A RU2014104384 A RU 2014104384A RU 2014104384/04 A RU2014104384/04 A RU 2014104384/04A RU 2014104384 A RU2014104384 A RU 2014104384A RU 2014104384 A RU2014104384 A RU 2014104384A
Authority
RU
Russia
Prior art keywords
adhd
sleep
daytime sleepiness
wakefulness
memory
Prior art date
Application number
RU2014104384/04A
Other languages
English (en)
Inventor
Ральф Глаттхар
Доналд Джонс
Даниель УМБРИХТ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2014104384A publication Critical patent/RU2014104384A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Фармацевтическая композиция для лечения, профилактики или задержки развития синдрома нарушения внимания с гиперактивностью (СНВГ), СНВГ детей, СНВГ взрослых, избыточной дневной сонливости, апноэ во сне, нарушения цикла сна и пробуждений у сменных работников, травматического повреждения мозга, нейродегенеративных расстройств и связанных с ними проблем с памятью и когнитивной функцией, синдрома хронической усталости, усталости, связанной с лишением сна или продолжительным бодрствованием, связанного с возрастом ухудшения памяти и когнитивной функции, когнитивного нарушения связанного с расстройством настроения, беспокойства, шизофрении и дневной сонливости, связанной с нарколепсией, включающая метиловый эфир (-)-(3aR,4S,7aR)-4-гидрокси-4-м-толилэтинилоктагидроиндол-1-карбоновой кислоты в форме свободного основания или кислотно-аддитивной соли.

Claims (1)

  1. Фармацевтическая композиция для лечения, профилактики или задержки развития синдрома нарушения внимания с гиперактивностью (СНВГ), СНВГ детей, СНВГ взрослых, избыточной дневной сонливости, апноэ во сне, нарушения цикла сна и пробуждений у сменных работников, травматического повреждения мозга, нейродегенеративных расстройств и связанных с ними проблем с памятью и когнитивной функцией, синдрома хронической усталости, усталости, связанной с лишением сна или продолжительным бодрствованием, связанного с возрастом ухудшения памяти и когнитивной функции, когнитивного нарушения связанного с расстройством настроения, беспокойства, шизофрении и дневной сонливости, связанной с нарколепсией, включающая метиловый эфир (-)-(3aR,4S,7aR)-4-гидрокси-4-м-толилэтинилоктагидроиндол-1-карбоновой кислоты в форме свободного основания или кислотно-аддитивной соли.
RU2014104384/04A 2006-09-11 2014-02-07 Производные никотиновой кислоты в качестве метаботропных глутаматных рецепторов RU2014104384A (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP06120424.4 2006-09-11
EP06120424 2006-09-11
US86881406P 2006-12-06 2006-12-06
US86880506P 2006-12-06 2006-12-06
US60/868,805 2006-12-06
US60/868,814 2006-12-06
US88525507P 2007-01-17 2007-01-17
US60/885,255 2007-01-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2009113258/04A Division RU2009113258A (ru) 2006-09-11 2007-09-10 Производные никотиновой кислоты в качестве метаботропных глутаматных рецепторов

Publications (1)

Publication Number Publication Date
RU2014104384A true RU2014104384A (ru) 2015-08-20

Family

ID=39184158

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014104384/04A RU2014104384A (ru) 2006-09-11 2014-02-07 Производные никотиновой кислоты в качестве метаботропных глутаматных рецепторов

Country Status (9)

Country Link
US (3) US20100041641A1 (ru)
EP (2) EP2272509A1 (ru)
JP (2) JP2010502664A (ru)
KR (1) KR20090061041A (ru)
AU (1) AU2007296964B2 (ru)
CA (1) CA2663113A1 (ru)
MX (1) MX2009002684A (ru)
RU (1) RU2014104384A (ru)
WO (1) WO2008031550A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2701853A1 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of parkinson's disease
AU2012254934B2 (en) * 2007-10-12 2013-10-17 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of Parkinson's disease
KR20110027817A (ko) * 2008-06-30 2011-03-16 노파르티스 아게 Ｍｇｌｕｒ 조절제를 포함하는 파킨슨병 치료용 조합물
CN102119151A (zh) * 2008-08-12 2011-07-06 诺瓦提斯公司 4-氧代-八氢-吲哚-1-羧酸甲基酯及其衍生物的制备方法
BR112012006330A2 (pt) * 2009-09-21 2017-07-04 Janssen Cilag S A análogos de o-benzil nicotinamida como moduladores alostéricos positivos de mglur5
WO2012084873A1 (en) * 2010-12-20 2012-06-28 Novartis Ag 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
AU2015314851B2 (en) * 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
EP1165084A4 (en) 1999-03-03 2002-05-15 Merck & Co Inc PRENYL PROTEIN TRANSFERASES INHIBITORS
CN1361768A (zh) * 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
AU2003259068B2 (en) 2002-08-09 2009-07-02 Astrazeneca Ab "1,2,4"oxadiazoles as modulators of metabotropic glutamate receptor-5
ATE415390T1 (de) * 2003-03-04 2008-12-15 Addex Pharma Sa Neue aminopyridinderivate als mglur5-antagonisten
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
CA2549969A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
CN1870999A (zh) 2003-10-31 2006-11-29 阿斯利康(瑞典)有限公司 炔烃ⅰ
WO2005044265A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
CN1933838A (zh) 2004-02-12 2007-03-21 默克公司 作为代谢型谷氨酸受体－5调节剂的联吡啶酰胺
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
TW200801005A (en) 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
CA2627630A1 (en) * 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors

Also Published As

Publication number Publication date
EP2069305A2 (en) 2009-06-17
JP5860865B2 (ja) 2016-02-16
AU2007296964A1 (en) 2008-03-20
US20100041641A1 (en) 2010-02-18
KR20090061041A (ko) 2009-06-15
EP2272509A1 (en) 2011-01-12
JP2014088404A (ja) 2014-05-15
WO2008031550A3 (en) 2008-08-21
JP2010502664A (ja) 2010-01-28
US20140187600A1 (en) 2014-07-03
US20120309742A1 (en) 2012-12-06
WO2008031550A2 (en) 2008-03-20
MX2009002684A (es) 2009-06-05
CA2663113A1 (en) 2008-03-20
AU2007296964B2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
RU2014104384A (ru) Производные никотиновой кислоты в качестве метаботропных глутаматных рецепторов
HRP20201243T1 (hr) N-piperidinil acetamidni derivati kao blokatori kalcijevog kanala
EA201070534A1 (ru) Стабилизированная суспензия каризбамата для применения в педиатрии
CY1124111T1 (el) Παραγοντες ρυθμισης γλουταμικου στην αντιμετωπιση ψυχικων διαταραχων
NO20064642L (no) Anvendelse av (S,S)- eller racemisk reboxetin
DE602005015862D1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
AR056879A1 (es) Antagonistas del receptor 3 de la histamina
CL2008003399A1 (es) Compuestos derivados de bis-(sulfonilamino), moduladores de la actividad de la sintasa de prostaglandina e1 microsomal; proceso de preparacion; composicion farmaceutica; proceso de preparacion; y uso en el tratamiento de dolor, osteoartritis, neoplasias, apnea, muerte subita del lactante, alzheimer, entre otars.
JP2007507065A5 (ru)
RS52754B (en) MALATE IS N- (4- {[6,7-BIS (METHYLOXY) HINOLIN-4-IL] OXY} PHENYL-N'- (4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMID, AND ITS CRYSTAL FORMS FOR CARCINOMA TREATMENT
CO5700765A2 (es) 2-(piridin-2-ilamino)-pirido[2,3-d] pirimidin-7-onas
DK1848414T3 (da) Fremgangsmåde til behandling af gefitinib-resistent cancer
DE602005018981D1 (de) Verfahren zur Herstellung von L-Cystein, und L-Cystein-produzierender Mikroorganismus
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
DE602006009652D1 (de) Eine herstellungsmethode von entacapon-enthaltenden granulaten für orale dosierformen
BR112015022334A2 (pt) blocos de mordida ajustáveis
ATE546143T1 (de) Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
HRP20141046T1 (hr) Tricikliäśki spoj i njegova farmaceutska uporaba
EA200801488A1 (ru) Замещенные фенетиламины, обладающие серотонинергической и/или норэпинефринергической активностью
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
BR112016006229A2 (pt) ?sistema e método para detectar deglutição infantil?
JP2007516193A5 (ru)
HRP20210245T1 (hr) Primjena fk506 za liječenje plućne arterijske hipertenzije
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20170208